31,645 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Acquired by Nebula Research & Development LLC

Nebula Research & Development LLC purchased a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 31,645 shares of the company’s stock, valued at approximately $697,000.

Several other institutional investors have also added to or reduced their stakes in CLBT. NewEdge Advisors LLC raised its holdings in Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock worth $86,000 after purchasing an additional 3,352 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Cellebrite DI during the 4th quarter valued at about $100,000. Polen Capital Management LLC purchased a new stake in shares of Cellebrite DI during the 4th quarter valued at about $222,000. Victory Capital Management Inc. purchased a new stake in shares of Cellebrite DI during the 4th quarter valued at about $234,000. Finally, HighTower Advisors LLC bought a new position in shares of Cellebrite DI in the 4th quarter worth approximately $274,000. 45.88% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on CLBT shares. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of Cellebrite DI in a report on Wednesday, April 2nd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI presently has an average rating of “Buy” and an average price target of $23.43.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $19.78 on Tuesday. The business’s 50 day moving average price is $18.73 and its 200-day moving average price is $20.15. The company has a market cap of $4.74 billion, a P/E ratio of -14.23, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a fifty-two week low of $10.25 and a fifty-two week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, equities analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.